Metabolic Category
THE SATIETY SIGNAL
Acylated amylin analog
Cagrilintide is an amylin-mimicking peptide that strongly suppresses appetite and slows gastric emptying, working alongside GLP-1s to boost satiety and support sustained weight loss.
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
No. This profile records Cagrilintide as not FDA approved and for research use only.
Review the regulatory and source details on this page for the current context.
Dose: Start at 0.25 mg once weekly (subcutaneous), titrating toward 2.4 mg once weekly..
Schedule: weekly. Cycle: 8+ weeks (ongoing treatment). This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 6 curated or current research sources.
Inspect the research section and the citations beneath the research answers for their supporting sources.
Review the Cagrilintide research sourcesReported side effects of Cagrilintide include Mild nausea, Decreased appetite, and Injection site irritation.
They are reported or occasional reactions, not a prediction of what any one person will experience.
Cagrilintide has an editorial safety grade of B (Good Safety).
Well-tolerated in clinical trials. Being developed by Novo Nordisk. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
Cagrilintide is a long-acting amylin analogue that acts as a calcitonin (CTR)/amylin receptor (AMYR) agonist. In the studies described, cagrilintide is combined with semaglutide, a long-acting GLP-1 receptor agonist, in the fixed-ratio combination CagriSema. The combination was compared with placebo, cagrilintide alone, or semaglutide alone in overweight or obese individuals, and the reported effects on glycaemic control and bodyweight were described as complementary.
Cagrilintide is a calcitonin (CTR)/amylin receptor (AMYR) agonist, meaning it activates these receptors. In the fixed-ratio combination CagriSema, it is paired with the long-acting GLP-1R agonist semaglutide. A review describes cagrilintide as differing from other amylin-based agents in its pharmacokinetic properties and receptor selectivity, ranging from more selective amylin receptor agonists to dual amylin/calcitonin receptor agonists. The same review notes that calcitonin receptor engagement, exposure kinetics and downstream neural circuit recruitment may influence whether reduced food intake reflects physiological satiation or aversive signaling.
Activates satiety centers in the brain to reduce hunger
Delays stomach emptying so you feel full longer
Suppresses glucagon and improves insulin sensitivity
Cagrilintide is a chemically modified amylin peptide with an attached lipid group. The 2021 development paper describes a structure-design program focused on the tendency of amylin molecules to form amyloid fibrils, alongside changes to peptide stability and lipid attachment. This history places cagrilintide in amylin research rather than the GLP-1 peptide family.
[Cagrilintide development paper, 2021](https://pubmed.ncbi.nlm.nih.gov/34288673/)
People with obesity seeking medical weight loss · Type 2 diabetics needing better glucose control · Those who have plateaued on GLP-1 drugs alone · Anyone needing appetite suppression · People with metabolic syndrome
In-stock prices from 96 vendors, checked Oct 14, 2026.
Market evidence
We found certificates from some of the Cagrilintide vendors we track. Based on the certificates our crawler found; vendors may publish more than we index. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
Certificate assessment
1 evaluated certificates
1 graded · 0 not graded · 1 in the A range.
Each result belongs to the named vendor’s certificate. Grades assess the document and its reported tests, not the vendor’s whole catalog or the safety of a product.
Automated checks can make mistakes. Open “Why this result?” for the reason and any review notice, and check the linked COA’s lot against your product. How grading works
1 evaluated record
Document grade
B3: Most of the evidence is there, but the purity test method isn't shown, so the grade stops at A-.
Document check: flag.
Lab record: not confirmed.
Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2
CG201028
| COA grade | Printed lab | Certificate | |||
|---|---|---|---|---|---|
| retaone Lot: CG201028 | Document grade Why this result?B3: Most of the evidence is there, but the purity test method isn't shown, so the grade stops at A-. Document check: flag. Lab record: not confirmed. Graded Oct 14, 2026 · Grader 0.4.9 · Policy 2026-10-07.2 | KOVERA LABS | Oct 6, 2026 | 99.802%99.5%+ | View COA |
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
Boost metabolism and burn fat without changing your diet
from $0.50/mg · 195 vendorsNº 001 / 006Exercise in a peptide. Boost metabolism without the treadmill
from $1.20/mg · 313 vendorsNº 005 / 006FDA-approved for weight loss. Patients lose 20%+ of their body weight.
from $0.95/mg · 461 vendorsNº 006 / 006Exercise in a molecule. Activate your metabolism without the gym
from $0.64/mg · 20 vendorsNº 002 / 006Make your cells burn more fuel. Mitochondrial uncoupling for fat loss
Full profileNº 003 / 006An injectable blend that helps your liver process and burn fat
Full profileNº 004 / 006
